claw-methylation-cycle
Methylation cycle analysis skill for ClawBio. Produces enzymatic activity
profiles, Net Methylation Capacity (NMC), BH4 axis estimates, compound
heterozygosity detection, and clinician-review genotype findings from raw
SNP genotype data.
Trigger
Fire this skill when:
- The user asks about methylation, MTHFR variants, folate cycle, or
homocysteine risk from a genotype file.
- A raw SNP file (23andMe / ADNTRO / Ancestry format) is provided and the
clinical question involves methylation, BH4, dopamine/serotonin synthesis
capacity, or neurodevelopmental contexts (ADHD, depression, anxiety).
- The upstream workflow (PharmGx Reporter, NutriGx Advisor) has flagged
MTHFR or MTRR and the clinician needs the full methylation panel.
- Keywords present:
methylation, MTHFR, BH4, folate cycle,
metilación, ciclo de metilación, homocysteine, 5-MTHF,
methylcobalamin, neurotransmitter synthesis, dopamine upstream.
Do NOT fire this skill when:
- The question is purely about folic acid supplementation without a genotype file.
- The user is asking about MTHFR in the context of thrombophilia/clotting
only — use PharmGx Reporter for warfarin/anticoagulation questions.
- Only N-GENE polygenic risk data is available (no raw SNP file) — this skill
requires genotype-level input; PRS percentiles are not sufficient.
- The SNP file format is VCF, FASTQ, BAM, or PLINK binary — these require
preprocessing before this skill can run.
- The clinical question is exclusively pharmacogenomic (CYP enzymes) — use
PharmGx Reporter instead.
Workflow
Receive input — Accept either a raw genotype file path or a pre-parsed
snp_dict. If a file is provided, call parse_genotype_file() to extract
the rsID → genotype mapping.
Panel coverage check — Compare detected rsIDs against the 9-gene
methylation panel. Log missing SNPs. For any SNP absent from the input,
mark the corresponding gene as not_assessed — do NOT silently assume
normal activity (Safety Rule 6).
Enzymatic activity scoring — For each gene, map the diplotype to an
estimated activity percentage. Heterozygous risk variants reduce activity
by their assigned weight; homozygous variants apply the full reduction.
Compound heterozygosity detection — Check MTHFR C677T (rs1801133) and
A1298C (rs1801131) simultaneously. If both are heterozygous, set
compound_heterozygosity = True and apply the combined activity reduction
(~15% of normal — more severe than either variant alone).
Net Methylation Capacity (NMC) — Compute the weighted average of all
enzyme activities. Clamp to [0, 100]. Expose coverage_pct and
snps_missing; flag NMC as partial if key SNPs are absent.
BH4 axis capacity — Derive BH4 from MTHFR activity and MTRR modifier.
Report clinical implications for dopamine and serotonin synthesis in
neurodevelopmental presentations.
Prioritised recommendations — Generate PRIORITY 1 / 2 / 3
recommendations based on active findings. Lead with highest clinical
impact (compound het MTHFR or severely reduced BH4).
Output — Write report.md (human-readable) and result.json
(structured, for downstream integration).
Example Output
╔══════════════════════════════════════════════════════════════╗
║ ClawBio · Methylation Cycle Analysis Report ║
║ Author: Samuel Carmona Aguirre · RUO — Not a medical device ║
╚══════════════════════════════════════════════════════════════╝
Executive Summary
─────────────────
Net Methylation Capacity : 53 / 100 🔴 Reduced
BH4 Axis Capacity : 31 / 100 🔴 Reduced
MTHFR Compound Het. : YES ⚠️ (C677T + A1298C)
Dopamine Synthesis : Severely Reduced
Serotonin Synthesis : Severely Reduced
Enzymatic Activity Profile
──────────────────────────
Gene Activity Status Key Variants
MTHFR 15% 🔴 Severely reduced C677T, A1298C
MTRR 60% 🟡 Moderately reduced A66G
MTR 100% 🟢 Normal –
CBS 100% 🟢 Normal –
BHMT 40% 🔴 Moderately reduced R239Q
SHMT1 80% 🟢 Mildly reduced C1420T
COMT 55% 🟡 Moderately reduced Val158Met
AHCY 100% 🟢 Normal –
Clinical Recommendations — FOR CLINICIAN REVIEW ONLY
──────────────────────────────────────────────────────
⚠️ The following is genotype-based information for qualified clinician use.
Do not self-administer. All nutrients listed are reported in the peer-reviewed
literature for the pathways indicated; dosing and indication require
individualised clinical assessment.
Genotype findings:
• 5-MTHF (methylfolate) preferred over synthetic folic acid (MTHFR C677T/A1298C).
Ref: Lamers Y et al. (2004) Am J Clin Nutr 80(5):1234-41.
• MTHFR compound het: methylcobalamin co-administration reported in literature.
Ref: Ledford AW et al. (2021) Nutrients 13(3):768.
• BH4 capacity at 31%: riboflavin (B2) reported as MTHFR cofactor supporting BH4
regeneration. Ref: McNulty H et al. (2017) Am J Clin Nutr 106(1):128-36.
• MTRR A66G: methylcobalamin preferred over cyanocobalamin per functional studies.
Ref: Olteanu H et al. (2002) Biochemistry 41(45):13378-85.
• BHMT R239Q: betaine and choline-rich foods reported as alternative methyl donors.
Ref: Slow S et al. (2004) Clin Chim Acta 340(1-2):57-67.
Some literature reports an association between BH4 deficiency and
ADHD/depression/anxiety phenotypes. This genotype indicates reduced BH4
production capacity. A clinician should contextualise this finding with
the patient's clinical history.
Where clinically relevant, a clinician may evaluate whether neurodevelopmental
symptoms correlate with BH4 capacity for potential non-pharmacological support.
Gotchas
Missing SNPs must never be silently normalised. The current
implementation (line 471) defaults to assuming normal activity for SNPs
absent from the input. This produces an artificially high NMC. When key
SNPs are missing, always expose coverage_pct and snps_missing so
downstream consumers know the score is partial.
Compound heterozygosity is synergistic, not additive. C677T and A1298C
affect different MTHFR domains. Their combined effect (~15% activity) is
greater than either variant alone. Do not compute as
activity(677) × activity(1298).
BH4 capacity is an estimate, not a measured value. The BH4 score is
derived from MTHFR activity and literature-based weights. It does not
account for DHFR variation or dietary cofactor availability. Always
include the RUO disclaimer.
COMT Val158Met has a dual role. rs4680 appears in both methylation
(SAM consumption) and dopamine/catecholamine panels. Always note this —
do not report it in isolation.
DTC array coverage varies by platform. ADNTRO covers all 9 panel SNPs
for most European-ancestry samples. 23andMe v3 and Ancestry v1 may not
include rs1801394 (MTRR) or rs3733890 (BHMT). Always check snps_missing.
This skill does not cover pharmacogenomics. SLCO1B1, CYP enzymes, and
statin/warfarin risk belong to PharmGx Reporter, not this skill.
Domain Decisions
Genes and Variants Assessed
| Gene |
rsID |
Variant |
Allele Assessed |
Effect Direction |
| MTHFR |
rs1801133 |
C677T |
T (risk) |
Decreased MTHFR activity |
| MTHFR |
rs1801131 |
A1298C |
C (risk) |
Decreased MTHFR activity |
| MTRR |
rs1801394 |
A66G |
G (risk) |
Decreased MTRR activity |
| MTR |
rs1805087 |
A2756G |
G (risk) |
Decreased MTR activity |
| CBS |
rs234706 |
C699T |
T (risk) |
Increased CBS activity |
| BHMT |
rs3733890 |
R239Q |
A (risk) |
Decreased BHMT activity |
| SHMT1 |
rs1979277 |
C1420T |
T (risk) |
Decreased SHMT1 activity |
| COMT |
rs4680 |
Val158Met |
A/Met (risk) |
Decreased COMT activity |
| AHCY |
rs819147 |
AHCY |
T (risk) |
Decreased AHCY activity |
Enzymatic Activity Estimates
Activity is estimated as a percentage of normal function based on homozygous vs.
heterozygous status of risk alleles. These are approximations derived from published
functional studies — they are NOT direct enzyme assays.
| Genotype |
Estimated Activity |
| 0 risk alleles (WT) |
100% |
| 1 risk allele (het) |
60–80% (gene-specific, see below) |
| 2 risk alleles (hom) |
15–40% (gene-specific, see below) |
Gene-specific estimates (homozygous risk):
- MTHFR C677T homozygous: ~30% of normal
- MTHFR A1298C homozygous: ~60% of normal
- MTHFR compound heterozygous (C677T + A1298C): ~15% of normal
- MTRR A66G homozygous: ~60% of normal
- BHMT R239Q homozygous: ~40% of normal
- COMT Val158Met homozygous (Met/Met): ~25% of normal
- SHMT1 C1420T homozygous: ~60% of normal
Source: Nazki FH et al. (2014) Gene 533(1):11-20; Ledford AW et al. (2021) Nutrients 13(3):768.
Net Methylation Capacity (NMC) Score
NMC is a composite index (0–100) derived from weighted enzymatic activities:
- MTHFR: weight 0.35 (primary rate-limiting enzyme)
- MTRR: weight 0.15
- BHMT: weight 0.15
- COMT: weight 0.10
- MTR: weight 0.10
- CBS: weight 0.05 (inverse — upregulation diverts homocysteine)
- SHMT1: weight 0.05
- AHCY: weight 0.05
NMC < 40: Severely reduced
NMC 40–60: Moderately reduced
NMC 60–80: Mildly reduced
NMC > 80: Within normal range
Note (ACMG 2013): Routine population screening for MTHFR variants is not
recommended for thrombosis risk assessment. This tool reports genotype facts
for clinician contextualisation; NMC bands are descriptive outputs, not
intervention triggers. Clinical decisions require individual patient evaluation.
BH4 Axis Capacity
BH4 (tetrahydrobiopterin) is an essential cofactor for tyrosine hydroxylase
(dopamine) and tryptophan hydroxylase (serotonin). MTHFR activity directly
constrains BH4 regeneration via the folate cycle.
- Base BH4 capacity = MTHFR_activity × MTRR_modifier
- MTRR_modifier: homozygous risk = 0.75; heterozygous = 0.88; WT = 1.0
BH4 thresholds:
- < 40%: Severely reduced — neurotransmitter synthesis substantially constrained
- 40–65%: Moderately reduced — may be clinically relevant; clinician to contextualise
65%: Within normal range
Compound Heterozygosity
MTHFR compound heterozygous (C677T + A1298C simultaneously) is the most
clinically significant single-gene methylation finding. Total MTHFR activity
is reduced more than either variant alone. Flagged explicitly in output.
Author and Attribution
Developed by Samuel Carmona Aguirre (samuel@unimed-consulting.es) as part of a
contribution to the ClawBio open-source bioinformatics library.
Conflict of Interest (COI): The author develops clinical genomics workflows
in a private practice context and may use tools derived from this skill as a
component in those workflows. This skill is contributed as a standalone
open-source genotype reporting tool; its output is not specific to any
proprietary clinical platform. All clinical integration decisions rest with
the qualified end-user clinician.
ACMG caveat on MTHFR testing (Green et al., Genet Med 2013, 15:153–156):
Routine population screening for MTHFR variants is not currently recommended by
ACMG for assessment of thrombosis risk, neural tube defect risk, or psychiatric
phenotypes. Genotype findings from this tool should be interpreted in the context
of the individual patient's clinical history by a qualified clinician.
Safety Rules
- Never report a clinical diagnosis. Always include the RUO disclaimer.
- Never recommend specific drug dosages or prescribe medication changes.
- Always flag MTHFR compound heterozygous status as requiring clinical review.
- Flag BH4 capacity < 40% with an explicit neurodevelopmental warning.
- Never extrapolate to ancestries not represented in source studies
(validated primarily in European-ancestry populations).
- Unknown SNPs or SNPs not in the input must be reported as "Not assessed" —
never assume wildtype.
- All supplementation suggestions are Priority-ranked guidance for a clinician,
not direct patient instructions.
Agent Boundary
In Scope
- Genotype extraction for 9 methylation-cycle genes from raw DTC files
- Enzymatic activity estimation (percentage of normal function)
- Net Methylation Capacity (NMC) composite index calculation
- BH4 axis capacity estimation and neurotransmitter synthesis impact
- MTHFR compound heterozygosity detection and flagging
- Prioritised clinical recommendations for clinician review
- JSON output for integration with downstream clinical decision-support systems
Out of Scope
- Dosing recommendations (requires clinical context and prescribing authority)
- Diagnosis of methylation disorders or neurodevelopmental conditions
- Drug-drug interaction analysis (see PharmGx Reporter)
- Epigenetic state (methylation is a phenotype; this skill assesses genotype only)
- Whole-genome or whole-exome sequencing data (SNP array input only)
- Direct patient communication (output is for qualified clinician use)
Usage
python skills/claw-methylation-cycle/methylation_cycle.py \
--input path/to/genotype.txt \
--output results/
Output Structure
<output_dir>/
├── report.md
├── result.json
└── reproducibility/
├── commands.sh
├── environment.yml
└── checksums.sha256
References
- Nazki FH et al. (2014). Folate: metabolism, genes, polymorphisms. Gene, 533(1), 11-20.
- Ledford AW et al. (2021). MTHFR and BH4 pathway in neuropsychiatric disorders. Nutrients, 13(3):768.
- Stover PJ (2009). One-carbon metabolism-genome interactions. J Nutr, 139(12), 2402-5.
- Lamers Y et al. (2004). Supplementation with [6S]-5-methyltetrahydrofolate or folic acid equally reduces plasma total homocysteine. Am J Clin Nutr, 80(5):1234-41.
- McNulty H et al. (2017). Riboflavin lowers homocysteine in children and adults with common MTHFR polymorphism. Am J Clin Nutr, 106(1):128-36.
- Olteanu H et al. (2002). Differences in the efficiency of reductive methylation of cob(II)alamin. Biochemistry, 41(45):13378-85.
- Slow S et al. (2004). Plasma betaine and homocysteine. Clin Chim Acta, 340(1-2):57-67.
- Esteller M. (2014). Introduccion a la epigenetica. SEBBM, 179:4-6.
- Spuch C, Agis-Balboa RC. (2014). Epigenetica en neurociencias. SEBBM, 179:18-21.
- Green RC et al. (2013). ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet Med, 15(7):565-74.
- ClawBio (2026). https://github.com/ClawBio/ClawBio
Changelog
| Version |
Date |
Change |
| 0.1.0 |
2026-04-07 |
Initial release. Validated on ASES-2307-002. |
| 0.1.1 |
2026-04-14 |
Fixed SKILL.md per PR #133: single YAML block, added Trigger, Workflow, Example Output, Gotchas. Removed unused pandas. Documented line-471 design decision. |
| 0.1.2 |
2026-05-12 |
Framing revisions per Manuel Corpas review: reworded BH4 causal language to association-based; reformatted supplement list as clinician-review block with per-nutrient citations; added 6 DOIs; converted em-dashes to ASCII in test docstrings; removed duplicate top-level test file. |
| 0.1.3 |
2026-05-15 |
Per PR #133 third review: (1) removed all specific dosages from recommendations; (2) stripped Holomedicina/CAPS/UNIMED/MH-AIAP branding from YAML, description, trigger, example output, Domain Decisions, report header — kept as author attribution only; (3) reframed NMC and BH4 bands as descriptive outputs, not intervention triggers; (4) added ACMG 2013 caveat on routine MTHFR testing; (5) added author COI disclosure; (6) removed obsolete Gotcha #5 (pandas); (7) softened compound het "strongly indicated" language. |
1---2name: claw-methylation-cycle3license: MIT4metadata:5 source: https://skillmd.com/skills/clawbio/claw-methylation-cycle6 openclaw:7 requires:8 bins:9 - python310 env: null11 config: null12 always: false13 emoji: 🧬14 homepage: https://github.com/ClawBio/ClawBio15 os:16 - darwin17 - linux18 install: 'pip install -e .1920 '21 trigger_keywords:22 - methylation23 - MTHFR24 - folate cycle25 - BH426 - homocysteine27 - methylation cycle28 - metilación29 - neurotransmitter synthesis30 author: Samuel Carmona Aguirre <samuel@unimed-consulting.es>31 demo_data_path: demo_input.txt32 dependencies_python: '>=3.9'33 guideline_doi: 10.3390/nu1303076834 input_format: 23andme, adntro, ancestry35 output_format: markdown, json36 tags:37 - genomics38 - methylation39 - MTHFR40 - neurodevelopment41 trigger_keywords:42 - methylation43 - MTHFR44 - folate cycle45 - BH446 - homocysteine47 - methylation cycle48 - metilación49 - neurotransmitter synthesis50 validation_tier: community51 version: 0.1.352description: Methylation cycle analysis — enzymatic activity profiles, Net Methylation Capacity, BH4 axis estimates, compound heterozygosity detection from SNP genotype data.53---5455# claw-methylation-cycle5657Methylation cycle analysis skill for ClawBio. Produces enzymatic activity58profiles, Net Methylation Capacity (NMC), BH4 axis estimates, compound59heterozygosity detection, and clinician-review genotype findings from raw60SNP genotype data.6162---6364## Trigger6566**Fire this skill when:**6768- The user asks about methylation, MTHFR variants, folate cycle, or69 homocysteine risk from a genotype file.70- A raw SNP file (23andMe / ADNTRO / Ancestry format) is provided and the71 clinical question involves methylation, BH4, dopamine/serotonin synthesis72 capacity, or neurodevelopmental contexts (ADHD, depression, anxiety).73- The upstream workflow (PharmGx Reporter, NutriGx Advisor) has flagged74 MTHFR or MTRR and the clinician needs the full methylation panel.75- Keywords present: `methylation`, `MTHFR`, `BH4`, `folate cycle`,76 `metilación`, `ciclo de metilación`, `homocysteine`, `5-MTHF`,77 `methylcobalamin`, `neurotransmitter synthesis`, `dopamine upstream`.7879**Do NOT fire this skill when:**8081- The question is purely about folic acid supplementation without a genotype file.82- The user is asking about MTHFR in the context of thrombophilia/clotting83 only — use PharmGx Reporter for warfarin/anticoagulation questions.84- Only N-GENE polygenic risk data is available (no raw SNP file) — this skill85 requires genotype-level input; PRS percentiles are not sufficient.86- The SNP file format is VCF, FASTQ, BAM, or PLINK binary — these require87 preprocessing before this skill can run.88- The clinical question is exclusively pharmacogenomic (CYP enzymes) — use89 PharmGx Reporter instead.9091---9293## Workflow94951. **Receive input** — Accept either a raw genotype file path or a pre-parsed96 `snp_dict`. If a file is provided, call `parse_genotype_file()` to extract97 the rsID → genotype mapping.98992. **Panel coverage check** — Compare detected rsIDs against the 9-gene100 methylation panel. Log missing SNPs. For any SNP absent from the input,101 mark the corresponding gene as `not_assessed` — do NOT silently assume102 normal activity (Safety Rule 6).1031043. **Enzymatic activity scoring** — For each gene, map the diplotype to an105 estimated activity percentage. Heterozygous risk variants reduce activity106 by their assigned weight; homozygous variants apply the full reduction.1071084. **Compound heterozygosity detection** — Check MTHFR C677T (rs1801133) and109 A1298C (rs1801131) simultaneously. If both are heterozygous, set110 `compound_heterozygosity = True` and apply the combined activity reduction111 (~15% of normal — more severe than either variant alone).1121135. **Net Methylation Capacity (NMC)** — Compute the weighted average of all114 enzyme activities. Clamp to [0, 100]. Expose `coverage_pct` and115 `snps_missing`; flag NMC as partial if key SNPs are absent.1161176. **BH4 axis capacity** — Derive BH4 from MTHFR activity and MTRR modifier.118 Report clinical implications for dopamine and serotonin synthesis in119 neurodevelopmental presentations.1201217. **Prioritised recommendations** — Generate PRIORITY 1 / 2 / 3122 recommendations based on active findings. Lead with highest clinical123 impact (compound het MTHFR or severely reduced BH4).1241258. **Output** — Write `report.md` (human-readable) and `result.json`126 (structured, for downstream integration).127128---129130## Example Output131132```133╔══════════════════════════════════════════════════════════════╗134║ ClawBio · Methylation Cycle Analysis Report ║135║ Author: Samuel Carmona Aguirre · RUO — Not a medical device ║136╚══════════════════════════════════════════════════════════════╝137138Executive Summary139─────────────────140Net Methylation Capacity : 53 / 100 🔴 Reduced141BH4 Axis Capacity : 31 / 100 🔴 Reduced142MTHFR Compound Het. : YES ⚠️ (C677T + A1298C)143Dopamine Synthesis : Severely Reduced144Serotonin Synthesis : Severely Reduced145146Enzymatic Activity Profile147──────────────────────────148Gene Activity Status Key Variants149MTHFR 15% 🔴 Severely reduced C677T, A1298C150MTRR 60% 🟡 Moderately reduced A66G151MTR 100% 🟢 Normal –152CBS 100% 🟢 Normal –153BHMT 40% 🔴 Moderately reduced R239Q154SHMT1 80% 🟢 Mildly reduced C1420T155COMT 55% 🟡 Moderately reduced Val158Met156AHCY 100% 🟢 Normal –157158Clinical Recommendations — FOR CLINICIAN REVIEW ONLY159──────────────────────────────────────────────────────160⚠️ The following is genotype-based information for qualified clinician use.161 Do not self-administer. All nutrients listed are reported in the peer-reviewed162 literature for the pathways indicated; dosing and indication require163 individualised clinical assessment.164165Genotype findings:166 • 5-MTHF (methylfolate) preferred over synthetic folic acid (MTHFR C677T/A1298C).167 Ref: Lamers Y et al. (2004) Am J Clin Nutr 80(5):1234-41.168 • MTHFR compound het: methylcobalamin co-administration reported in literature.169 Ref: Ledford AW et al. (2021) Nutrients 13(3):768.170 • BH4 capacity at 31%: riboflavin (B2) reported as MTHFR cofactor supporting BH4171 regeneration. Ref: McNulty H et al. (2017) Am J Clin Nutr 106(1):128-36.172 • MTRR A66G: methylcobalamin preferred over cyanocobalamin per functional studies.173 Ref: Olteanu H et al. (2002) Biochemistry 41(45):13378-85.174 • BHMT R239Q: betaine and choline-rich foods reported as alternative methyl donors.175 Ref: Slow S et al. (2004) Clin Chim Acta 340(1-2):57-67.176177Some literature reports an association between BH4 deficiency and178ADHD/depression/anxiety phenotypes. This genotype indicates reduced BH4179production capacity. A clinician should contextualise this finding with180the patient's clinical history.181Where clinically relevant, a clinician may evaluate whether neurodevelopmental182symptoms correlate with BH4 capacity for potential non-pharmacological support.183```184185---186187## Gotchas1881891. **Missing SNPs must never be silently normalised.** The current190 implementation (line 471) defaults to assuming normal activity for SNPs191 absent from the input. This produces an artificially high NMC. When key192 SNPs are missing, always expose `coverage_pct` and `snps_missing` so193 downstream consumers know the score is partial.1941952. **Compound heterozygosity is synergistic, not additive.** C677T and A1298C196 affect different MTHFR domains. Their combined effect (~15% activity) is197 greater than either variant alone. Do not compute as198 `activity(677) × activity(1298)`.1992003. **BH4 capacity is an estimate, not a measured value.** The BH4 score is201 derived from MTHFR activity and literature-based weights. It does not202 account for DHFR variation or dietary cofactor availability. Always203 include the RUO disclaimer.2042054. **COMT Val158Met has a dual role.** rs4680 appears in both methylation206 (SAM consumption) and dopamine/catecholamine panels. Always note this —207 do not report it in isolation.2082095. **DTC array coverage varies by platform.** ADNTRO covers all 9 panel SNPs210 for most European-ancestry samples. 23andMe v3 and Ancestry v1 may not211 include rs1801394 (MTRR) or rs3733890 (BHMT). Always check `snps_missing`.2122136. **This skill does not cover pharmacogenomics.** SLCO1B1, CYP enzymes, and214 statin/warfarin risk belong to PharmGx Reporter, not this skill.215216---217218## Domain Decisions219220### Genes and Variants Assessed221222| Gene | rsID | Variant | Allele Assessed | Effect Direction |223|-------|-----------|-----------|-----------------|--------------------------|224| MTHFR | rs1801133 | C677T | T (risk) | Decreased MTHFR activity |225| MTHFR | rs1801131 | A1298C | C (risk) | Decreased MTHFR activity |226| MTRR | rs1801394 | A66G | G (risk) | Decreased MTRR activity |227| MTR | rs1805087 | A2756G | G (risk) | Decreased MTR activity |228| CBS | rs234706 | C699T | T (risk) | Increased CBS activity |229| BHMT | rs3733890 | R239Q | A (risk) | Decreased BHMT activity |230| SHMT1 | rs1979277 | C1420T | T (risk) | Decreased SHMT1 activity |231| COMT | rs4680 | Val158Met | A/Met (risk) | Decreased COMT activity |232| AHCY | rs819147 | AHCY | T (risk) | Decreased AHCY activity |233234### Enzymatic Activity Estimates235236Activity is estimated as a percentage of normal function based on homozygous vs.237heterozygous status of risk alleles. These are approximations derived from published238functional studies — they are NOT direct enzyme assays.239240| Genotype | Estimated Activity |241|----------------------|-----------------------------------------|242| 0 risk alleles (WT) | 100% |243| 1 risk allele (het) | 60–80% (gene-specific, see below) |244| 2 risk alleles (hom) | 15–40% (gene-specific, see below) |245246Gene-specific estimates (homozygous risk):247248- MTHFR C677T homozygous: ~30% of normal249- MTHFR A1298C homozygous: ~60% of normal250- MTHFR compound heterozygous (C677T + A1298C): ~15% of normal251- MTRR A66G homozygous: ~60% of normal252- BHMT R239Q homozygous: ~40% of normal253- COMT Val158Met homozygous (Met/Met): ~25% of normal254- SHMT1 C1420T homozygous: ~60% of normal255256Source: Nazki FH et al. (2014) Gene 533(1):11-20; Ledford AW et al. (2021) Nutrients 13(3):768.257258### Net Methylation Capacity (NMC) Score259260NMC is a composite index (0–100) derived from weighted enzymatic activities:261262- MTHFR: weight 0.35 (primary rate-limiting enzyme)263- MTRR: weight 0.15264- BHMT: weight 0.15265- COMT: weight 0.10266- MTR: weight 0.10267- CBS: weight 0.05 (inverse — upregulation diverts homocysteine)268- SHMT1: weight 0.05269- AHCY: weight 0.05270271NMC < 40: Severely reduced272NMC 40–60: Moderately reduced273NMC 60–80: Mildly reduced274NMC > 80: Within normal range275276> **Note (ACMG 2013):** Routine population screening for MTHFR variants is not277> recommended for thrombosis risk assessment. This tool reports genotype facts278> for clinician contextualisation; NMC bands are descriptive outputs, not279> intervention triggers. Clinical decisions require individual patient evaluation.280281### BH4 Axis Capacity282283BH4 (tetrahydrobiopterin) is an essential cofactor for tyrosine hydroxylase284(dopamine) and tryptophan hydroxylase (serotonin). MTHFR activity directly285constrains BH4 regeneration via the folate cycle.286287- Base BH4 capacity = MTHFR_activity × MTRR_modifier288- MTRR_modifier: homozygous risk = 0.75; heterozygous = 0.88; WT = 1.0289290BH4 thresholds:291- < 40%: Severely reduced — neurotransmitter synthesis substantially constrained292- 40–65%: Moderately reduced — may be clinically relevant; clinician to contextualise293- > 65%: Within normal range294295### Compound Heterozygosity296297MTHFR compound heterozygous (C677T + A1298C simultaneously) is the most298clinically significant single-gene methylation finding. Total MTHFR activity299is reduced more than either variant alone. Flagged explicitly in output.300301### Author and Attribution302303Developed by Samuel Carmona Aguirre (samuel@unimed-consulting.es) as part of a304contribution to the ClawBio open-source bioinformatics library.305306**Conflict of Interest (COI):** The author develops clinical genomics workflows307in a private practice context and may use tools derived from this skill as a308component in those workflows. This skill is contributed as a standalone309open-source genotype reporting tool; its output is not specific to any310proprietary clinical platform. All clinical integration decisions rest with311the qualified end-user clinician.312313**ACMG caveat on MTHFR testing (Green et al., Genet Med 2013, 15:153–156):**314Routine population screening for MTHFR variants is not currently recommended by315ACMG for assessment of thrombosis risk, neural tube defect risk, or psychiatric316phenotypes. Genotype findings from this tool should be interpreted in the context317of the individual patient's clinical history by a qualified clinician.318319---320321## Safety Rules3223231. Never report a clinical diagnosis. Always include the RUO disclaimer.3242. Never recommend specific drug dosages or prescribe medication changes.3253. Always flag MTHFR compound heterozygous status as requiring clinical review.3264. Flag BH4 capacity < 40% with an explicit neurodevelopmental warning.3275. Never extrapolate to ancestries not represented in source studies328 (validated primarily in European-ancestry populations).3296. Unknown SNPs or SNPs not in the input must be reported as "Not assessed" —330 never assume wildtype.3317. All supplementation suggestions are Priority-ranked guidance for a clinician,332 not direct patient instructions.333334---335336## Agent Boundary337338### In Scope339340- Genotype extraction for 9 methylation-cycle genes from raw DTC files341- Enzymatic activity estimation (percentage of normal function)342- Net Methylation Capacity (NMC) composite index calculation343- BH4 axis capacity estimation and neurotransmitter synthesis impact344- MTHFR compound heterozygosity detection and flagging345- Prioritised clinical recommendations for clinician review346- JSON output for integration with downstream clinical decision-support systems347348### Out of Scope349350- Dosing recommendations (requires clinical context and prescribing authority)351- Diagnosis of methylation disorders or neurodevelopmental conditions352- Drug-drug interaction analysis (see PharmGx Reporter)353- Epigenetic state (methylation is a phenotype; this skill assesses genotype only)354- Whole-genome or whole-exome sequencing data (SNP array input only)355- Direct patient communication (output is for qualified clinician use)356357---358359## Usage360361```bash362python skills/claw-methylation-cycle/methylation_cycle.py \363 --input path/to/genotype.txt \364 --output results/365```366367---368369## Output Structure370371```372<output_dir>/373├── report.md374├── result.json375└── reproducibility/376 ├── commands.sh377 ├── environment.yml378 └── checksums.sha256379```380381---382383## References384385- Nazki FH et al. (2014). Folate: metabolism, genes, polymorphisms. *Gene*, 533(1), 11-20.386- Ledford AW et al. (2021). MTHFR and BH4 pathway in neuropsychiatric disorders. *Nutrients*, 13(3):768.387- Stover PJ (2009). One-carbon metabolism-genome interactions. *J Nutr*, 139(12), 2402-5.388- Lamers Y et al. (2004). Supplementation with [6S]-5-methyltetrahydrofolate or folic acid equally reduces plasma total homocysteine. *Am J Clin Nutr*, 80(5):1234-41.389- McNulty H et al. (2017). Riboflavin lowers homocysteine in children and adults with common MTHFR polymorphism. *Am J Clin Nutr*, 106(1):128-36.390- Olteanu H et al. (2002). Differences in the efficiency of reductive methylation of cob(II)alamin. *Biochemistry*, 41(45):13378-85.391- Slow S et al. (2004). Plasma betaine and homocysteine. *Clin Chim Acta*, 340(1-2):57-67.392- Esteller M. (2014). Introduccion a la epigenetica. *SEBBM*, 179:4-6.393- Spuch C, Agis-Balboa RC. (2014). Epigenetica en neurociencias. *SEBBM*, 179:18-21.394- Green RC et al. (2013). ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. *Genet Med*, 15(7):565-74.395- ClawBio (2026). https://github.com/ClawBio/ClawBio396397---398399## Changelog400401| Version | Date | Change |402|---------|------------|--------|403| 0.1.0 | 2026-04-07 | Initial release. Validated on ASES-2307-002. |404| 0.1.1 | 2026-04-14 | Fixed SKILL.md per PR #133: single YAML block, added Trigger, Workflow, Example Output, Gotchas. Removed unused pandas. Documented line-471 design decision. |405| 0.1.2 | 2026-05-12 | Framing revisions per Manuel Corpas review: reworded BH4 causal language to association-based; reformatted supplement list as clinician-review block with per-nutrient citations; added 6 DOIs; converted em-dashes to ASCII in test docstrings; removed duplicate top-level test file. |406| 0.1.3 | 2026-05-15 | Per PR #133 third review: (1) removed all specific dosages from recommendations; (2) stripped Holomedicina/CAPS/UNIMED/MH-AIAP branding from YAML, description, trigger, example output, Domain Decisions, report header — kept as author attribution only; (3) reframed NMC and BH4 bands as descriptive outputs, not intervention triggers; (4) added ACMG 2013 caveat on routine MTHFR testing; (5) added author COI disclosure; (6) removed obsolete Gotcha #5 (pandas); (7) softened compound het "strongly indicated" language. |